Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992471 | PMC |
| http://dx.doi.org/10.5021/ad.2018.30.5.641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.
Immune-mediated necrotizing myopathy: an emerging disorder.
Neurologia (Engl Ed)
September 2025
Unidad de ELA-Neuromuscular, Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; IiSGM, Instituto de Investigación Sanitaria Gregorio Marañón.
Objectives: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM).
Methods: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021.
Results: Sixteen IMNM cases were diagnosed, with a median age of 71.
Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study.
Semin Arthritis Rheum
August 2025
Grupo IRIDIS (Investigation in Rheumatology and Immune-Diseases), Instituto de Investigación Sanitaria Galicia Sur, (IISGS), Hospital Universitario Vigo, Vigo, Spain.
Introduction: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where cluster analysis of autoantibodies could identify prognostic subtypes.
Objectives: To define and describe serological clusters and their clinical-epidemiological characteristics, as well as their association with comorbidities, disease activity measures, severity, and damage.
Atypical Fibrodysplasia Ossificans Progressiva with G328E Variant and Digit Reduction Abnormalities: A Report of 2 Cases.
JBJS Case Connect
July 2025
Department of Radiology, Christian Medical College, Vellore, Tamil Nadu, India.
Case: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant musculoskeletal disorder with progressive heterotopic ossification within soft connective tissues causing ankyloses and unique skeletal malformations of the big toes, which represent a birth hallmark for the disease. The classic variant is c.617G>A (p.
View Article and Find Full Text PDFStatin-Associated Necrotizing Autoimmune Myopathy: Unmasking 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Antibody-Positive Disease After Statin Re-exposure.
Cureus
August 2025
Internal Medicine, Overlook Medical Center, Summit, USA.
Necrotizing autoimmune myopathy (NAM) is an uncommon inflammatory muscle disease marked by progressive weakness and elevated muscle enzymes. In some individuals, it may develop in association with statin use, particularly when specific autoantibodies are present. We report the case of a 65-year-old man who experienced worsening, painless proximal muscle weakness and significant creatine kinase (CK) elevation shortly after resuming statin therapy following a temporary discontinuation.
View Article and Find Full Text PDF